masthead-publications

Categories

Filter by Topics

ABC-DLBCL ADCC Gene Alteration Airway Remodeling AKT Targeted Therapy ALK Alleles Angiogenesis Anti-TNF Alpha Therapy Anus Apoptosis AR-Specific T Cells Asthma Autocrine Signaling Autoimmune Disorder AXL B-cell lines B-cell lymphoma Biofluid Biology of neoplasia Biomarker Biomarker Analysis Biomarker Discovery Biomarker Patient Stratification Biomarker Validation Biomarkers Biomarkers Outcome Bladder Bladder Cancer blood Brain Brain RNA Breast Breast Cancer Cancer Immune Response Carcinoma Cardio Vascular Disease Cardiometabolic Traits cardiovascular disease CD-19 CD44 CDKN2A mutation Cell line Cells Cerebral Spinal Fluid Checkpoint Inhibitors Chemoresistance Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating Tumor Cells Classification Clinical Outcome Prediction Clinical Trials cMET Coccidioidomycosis Colon Colon cancer Colorectal cancer Comparative Approach Comparative Study Comparison study Comprehensive Gene Expression Study Cord Blood Buffy Coat Core Needle Biopsy Custom mRNA Cyclin E mRNA Cytokines Detection Developmental Immunotherapy Diabetes Diagnostic Biomarkers Differential Diagnosis Differential Expression Differential Gene Expression Analysis Diffuse large B-cell lymphoma Dissecting Genomic Biomarkers DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT EMT-mediated resistance Encephalophy Epidemiology outcomes Epigenetics Epigenomic Epstein-Barr ERBB2 Esophageal Cancer Exosomes Extracellular Vesicles Extracted RNA Fabry Disease Feasibility FFPE FFPE Canine Tumor FGF Ligand Trap FGFR Fibrous Tumors Gastrointestinal Cancers Gene Expression Analysis Gene Expression Comparisons Gene Expression Profiling Gene Expression Signatures Gene Fusions Gene Pathway Analysis Genetic Polymorphism Genomic Genomic Bioinformatics Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E HPV HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBLCL Cell of Origin Assay HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Human Human serum Hypoxia Immune Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Signature Immune Tolerance Immune-checkpoint blockade Immune-related Colitis Immuno-Oncology Immunofluorescence Immunology Immunotherapy Induction Chemotherapy Inflammation Inflammatory Signatures Interferon Gamma Signature Invasive Breast Carcinoma Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lung Adenocarcinoma Lung cancer Lung Carcinoma Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Metastatic Colon Cancer Metastatic Prostate Cancer Methods Comparison Mice Mice PDX Microenvironment miRNA miRNA WTA miRQC study Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mRNA expression in tumors mTOR pathway mTORC1 mTORC2 Mucin Hypersecretion Multiple Myeloma Muscle Mutations MYC Myocardial Reperfusion Myocarditis NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Nivolumab non-Hodgkin Lymphoma Non-small Cell Lung Cancer Novel Therapeutic Targets NSCLC NTRK1 Oesophageal Adenocarcinoma Oncogenes Oncology Oncomirs Oral Cancer Oral Squamous Cell Carcinoma Osteoclast Ovarian cancer Overexpression P13KmTOR Inhibitor Palbociclib Pancreas Pancreatic Cancer Pancreatic Ductal Adenocarcinoma Pancreatic ductal adenocarcinoma Paralysis Parkinson's Disease Pathogenesis Pathology Pathway Analysis Pathways PCA Cell Lines PD-1 Pd-L1 PD-L1 Phase 3 clinical trial PI3K signaling pathway PIK3CA mutation Plasma plasma Platform Comparison Pralatrexate predictive Predictive Biomarkers Predictive Modeling Pro-inflammatory cytokines Profiling Profiling Signature Development Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radiation Toxicities Radioimmunotherapy Rearrangements rectum Regulation Renal Cell Carcinoma Renal Disease Responders vs Non-responders Response rate RET Reveal Rheumatoid Arthritis Risk Score Rituximab ROS1 safety Sarcoidosis Sarcoma SCBC SCLC Serum Signaling Inhibitors Signaling Pathways Signature Development Signature Pathway Analysis Signature Validation Signatures Sinonasal Undifferentiated Carcinoma Skin Small bowel Small cell bladder cancer Small Cell Bladder Cancer Small Cell Lung Cancer SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid System Validation Systemic Lupus Erythematousus T cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Tissue-based biomarkers TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Triple Negative Breast Cancer Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor mutational burden Tumor Mutational Burden Type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR Venetoclas Vistusertib WNT Path Signaling Xenograft Tissue

2014

Epithelial and stromal expression of miRNAs during prostate cancer progression.

Ren Q., et al. Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res. 2014 Jul 18;6(4):329-39.

PMID: 25075250

View External Link

Correlation of multiplex measurement of mRNA expression from FFPE tissues with protein expression.

Shell S., et al. Correlation of multiplex measurement of mRNA expression from FFPE tissues with protein expression. J Clin Oncol. 32, 2014;32(Suppl):abstr e22141.

View External Link

FGFR and FGF ligand overexpression in lung cancer: Implications for targeted therapy.

Maddula K., et al. FGFR and FGF ligand overexpression in lung cancer: Implications for targeted therapy. J Clin Oncol. 2014;32(Suppl 5):abstr 11080.

Download pdf 3.8MB
View External Link

Blood test to Monitor for the Absence of Acute Cardiac Rejection: From Discovery to Clinical Implementation

Hollander Z., et al. Blood test to Monitor for the Absence of Acute Cardiac Rejection: From Discovery to Clinical Implementation. J Heart Lung Transplant. 2014 Apr; 32(Suppl 4).

View External Link

RNA expression based screening of ALK Gene Fusion from NSCLC FFPE samples.

Maddula K., et al. RNA expression based screening of ALK Gene Fusion from NSCLC FFPE samples. Cancer Res. 2014;74(19 Suppl):abstr 1904. 

Download pdf 2.0MB
View External Link

In Vivo Molecular Markers for Pro-inflammatory Cytokine M1 Stage and Resident Microglia in Trimethyltin-Induced Hippocampal Injury.

McPherson C., et al. In Vivo Molecular Markers for Pro-inflammatory Cytokine M1 Stage and Resident Microglia in Trimethyltin-Induced Hippocampal Injury. Neurotox Res. 2014 Jan 25(1):45-56.

PMID: 24002884

View External Link

2013

Development of an automated RNA-based nuclease protection assay for the detection of expressed EML-ALK fusions, EGFR and KRAS mutations in NSCLC.

Rounseville M., et al. Development of an automated RNA-based nuclease protection assay for the detection of expressed EML-ALK fusions, EGFR and KRAS mutations in NSCLC. J Clin Oncol. 2013;31(Suppl); abstr e22185.

View External Link

miRNA Biomarker Identification Using a Sequencing-Based Nuclease Protection Assay (NPSeq™).

Seligmann B., et al. miRNA Biomarker Identification Using a Sequencing-Based Nuclease Protection Assay (NPSeq™). J Biomol Tech. 2013 May;24(Suppl).

Download pdf 677KB
View External Link

Targeted gene expression sequencing from FFPE: NPSeq™.

Thompson D., et al. Targeted gene expression sequencing from FFPE: NPSeq™. Cancer Res. 2013;73(8 Suppl):abstr 4146.

View External Link

Page last updated April 06, 2020